IRIS
BUEMI, MARIAROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.154
EU - Europa 2.093
AS - Asia 1.071
SA - Sud America 310
Continente sconosciuto - Info sul continente non disponibili 109
AF - Africa 33
Totale 5.770
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.116
RU - Federazione Russa 1.134
SG - Singapore 416
CN - Cina 365
BR - Brasile 269
IE - Irlanda 256
SE - Svezia 233
IT - Italia 157
HK - Hong Kong 118
FR - Francia 66
DE - Germania 54
GB - Regno Unito 52
VN - Vietnam 48
FI - Finlandia 39
IN - India 39
UA - Ucraina 23
BE - Belgio 21
AR - Argentina 17
CA - Canada 17
MX - Messico 13
ZA - Sudafrica 13
BD - Bangladesh 12
IQ - Iraq 12
MA - Marocco 11
CZ - Repubblica Ceca 10
PL - Polonia 10
TR - Turchia 10
EC - Ecuador 8
JP - Giappone 7
AE - Emirati Arabi Uniti 6
SA - Arabia Saudita 6
ES - Italia 5
ID - Indonesia 5
NL - Olanda 5
CL - Cile 4
MY - Malesia 4
AT - Austria 3
BO - Bolivia 3
CH - Svizzera 3
GR - Grecia 3
JO - Giordania 3
LK - Sri Lanka 3
LU - Lussemburgo 3
PK - Pakistan 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
AM - Armenia 2
AZ - Azerbaigian 2
CO - Colombia 2
DZ - Algeria 2
LV - Lettonia 2
NO - Norvegia 2
PE - Perù 2
TN - Tunisia 2
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
CG - Congo 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
EE - Estonia 1
EG - Egitto 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
LB - Libano 1
LT - Lituania 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
UY - Uruguay 1
VE - Venezuela 1
Totale 5.662
Salva come PNG Salva come JPEG
Città #
Ashburn 358
Moscow 334
Dublin 256
Singapore 228
Dallas 197
Chandler 190
Nyköping 168
Beijing 131
Hong Kong 117
San Jose 111
Ann Arbor 75
Jacksonville 70
Messina 70
The Dalles 60
Council Bluffs 47
Los Angeles 47
Princeton 40
Lauterbourg 36
Medford 36
Cambridge 33
Des Moines 27
Dearborn 23
Jinan 23
New York 21
Boardman 20
Brussels 19
São Paulo 17
Hyderabad 16
Orem 16
Guangzhou 15
Munich 15
Tianjin 15
Redondo Beach 14
San Mateo 14
Shenyang 14
Wilmington 14
Buffalo 13
Denver 13
Santa Clara 13
Brooklyn 12
Catania 11
Ho Chi Minh City 11
Ningbo 11
Rio de Janeiro 11
Seattle 11
Woodbridge 11
Francofonte 10
Johannesburg 10
Frankfurt am Main 9
Phoenix 9
Taizhou 9
Belo Horizonte 8
Brasília 8
Brno 8
Fuzhou 8
Haikou 8
Houston 8
Atlanta 7
Chicago 7
Hangzhou 7
Hanoi 7
London 7
Montreal 7
Pune 7
Boston 6
Düsseldorf 6
Hebei 6
Jiaxing 6
Turku 6
Warsaw 6
Baghdad 5
Guayaquil 5
Helsinki 5
Lancaster 5
Nanjing 5
North Bergen 5
Porto Alegre 5
Rome 5
Shanghai 5
Tokyo 5
Zhengzhou 5
Agadir 4
Bexley 4
Biên Hòa 4
City of London 4
Helena 4
Manchester 4
Mexico City 4
Milan 4
Nanchang 4
Nova Iguaçu 4
Nuremberg 4
Riyadh 4
Salvador 4
Washington 4
Amman 3
Athens 3
Bellflower 3
Charlotte 3
Clearwater 3
Totale 3.310
Salva come PNG Salva come JPEG
Nome #
Chemical exploration of 4-(4-fluorobenzyl)piperidine fragment for the development of new tyrosinase inhibitors 266
Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives 236
Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases 221
Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments 210
Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety 197
InVivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents 193
Discovery of a new potent inhibitor of mushroom tyrosinase (Agaricus bisporus) containing 4-(4-hydroxyphenyl)piperazin-1-yl moiety 193
Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis 189
Carbonic anhydrase inhibitors: Design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms 188
Design and optimization of isoquinoline-sulfonamides as potent and selective inhibitors of human carbonic anhydrase VII 186
Graphene Quantum Dots Based Systems As HIV Inhibitors 170
DISCOVERY OF NEW INDOLE DERIVATES AS NEUROPROTECTIVE AGENTS 168
From NMDA receptor antagonists to discovery of selective σ2 receptor ligands 162
Nuovi ligandi del recettore NR2B/NMDA a struttura indolica 156
Probing the molecular interactions between the human Carbonic Anhydrases (hCAs) and a novel class of benzenesulfonamides 151
Serendipitous discovery of indole derivatives as potent tyrosinase inhibitors 149
New indole derivatives as promising ligands for ifenprodil site of NR2B/NMDA receptors 145
Discovery and optimization of isoquinoline-derived inhibitors of human Carbonic Anhydrases (hCAs) 143
Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides 142
Computational and synthetic approaches for developing Lavendustin B derivatives as allosteric inhibitors of HIV-1 integrase 141
Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains 141
Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors 141
Rational design, synthesis and evaluation of coumarin derivatives as protein-protein interaction inhibitors 136
Design, Synthesis and Biostructural Characterization of Carbonic Anhydrase Inhibitors 133
Synthesis and biological characterization of novel potent arylsulfonamides as human carbonic anhydrase inhibitors (hCAIs) targeting central nervous system 132
Identification of 3-substituted-1H-indoles as ligands of GluN2B containing N-methyl-D-aspartate receptors 131
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: Synthesis, biological evaluation, and molecular modeling studies 131
Searching for NR2B/NMDA Receptor Antagonists As Neuroprotective Agents 126
Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening 125
Synthesis, biological evaluation and docking studies of NR2B/NMDA receptor antagonists 124
Synthesis and Biological Characterization of 3-Substituted-1H-indoles as Ligands of GluN2B-Containing N-Methyl-d-aspartate Receptors 115
Progettazione e sintesi di antagonisti non competitivi del recettore NR2B/NMDA 107
Synthesis, Modelling and Biological Characterization of 3-Substituted-1H-indoles as Ligands of GluN2B-containing N-Methyl-d-Aspartate Receptors 98
Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-d-aspartate receptor (NMDAR) containing GluN2B subunit 98
SYNTHESIS AND BIOLOGICAL CHARACTERIZATION OF NEW NR2B/NMDA RECEPTOR LIGANDS 92
Synthesis and Biological Characterization of 3-Substituted-1H-indoles as Ligands of GluN2B-containing N-Methyl-D-Aspartate Receptors. Part. 2. 87
SYNTHESIS AND BIOLOGICAL CHARACTERIZATION OF 3-SUBSTITUTED-1H-INDOLES AS LIGANDS OF GLUN2B-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS 86
Targeting GluN2B-containing N-Methyl-D-aspartate receptors: design, synthesis, and binding affinity evaluation of novel 3-substituted indoles. 81
Rational Design and synthesis of new GluN2B/NMDA receptor ligands as neuroprotective agents. 80
Totale 5.770
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.826
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.826
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022262 0 0 0 0 1 1 46 16 5 8 106 79
2022/2023730 46 65 33 75 57 61 14 30 328 2 16 3
2023/2024188 11 25 9 48 11 44 0 8 0 17 0 15
2024/2025752 15 8 15 45 42 14 12 164 182 52 81 122
2025/20262.616 109 207 156 214 237 585 283 319 306 115 29 56
2026/2027409 41 176 102 89 1 0 0 0 0 0 0 0
Totale 5.770